<scp>ALT</scp> flares during nucleotide analogue therapy are associated with <scp>HB</scp>sAg loss in genotype A <scp>HB</scp>eAg‐positive chronic hepatitis B

Abstract

In genotype A subjects undergoing long-term NA therapy, ALT flares predict for HBsAg response. The delay between ALT flare and HBsAg loss has implications for clinical trial design for early phase development of immunomodulatory strategies aiming for HBsAg loss.